Hikal Upgrades cGMP Pilot Plant to Boost Pharma R&D Capabilities
Hikal Limited has upgraded its cGMP-compliant pilot plant at its Pune Research & Technology campus, significantly boosting its ability to support global pharmaceutical clients through every stage of drug development. The expanded facility bridges the gap between laboratory research and commercial production, helping companies streamline technology transfers, speed up development timelines, and produce high-quality materials for preclinical and clinical trials while adhering to international regulatory standards. By unifying development and manufacturing at a single campus, the state-of-the-art plant encourages seamless collaboration between scientists and engineers. Equipped with versatile reactors ranging from 20 to 2,000 liters and specialized technology—including cryogenic, hydrogenation, and high-vacuum distillation systems—the facility handles a wide array of complex chemical processes. This investment reinforces Hikal’s standing as a reliable CDMO partner and advances India’s position in the global contract research and life sciences sectors. $HIKAL